Ziftomenib

3 trials 3 recruiting Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

2 Sponsors

12 Countries

Phase III

Phase I (Other)

Phase I (FiH)

Phase III: 1 Phase I (Other): 1 Phase I (FiH): 1

Indications tested

Acute myeloid leukaemia 1

Sponsors using this IMP

Kura Oncology Inc. 2 Prinses Maxima Centrum voor Kinderoncologie B.V. 1

All trials

3 total

Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 Phase III 10 countries Kura Oncology Inc.
A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting

2023-510509-17-00 Phase I (FiH) 6 countries Kura Oncology Inc.
Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting

2023-505262-28-00 Phase I (Other) 5 countries Prinses Maxima Centrum voor Kinderoncologie B.V.

Showing 1–3 of 3 trials

← All drugs A–Z